{"product_id":"cjc-1295-and-ipamorelin-blend-10mg-no-dac-biolongevity-labs","title":"CJC 1295 \u0026 Ipamorelin Blend (No DAC) X 10mg","description":"\u003cp\u003eDescription--\u003c!--StartFragment --\u003eCJC-1295 \u0026amp; Ipamorelin Blend - Growth Hormone Secretagogue Research Complex (10 mg, No DAC)\u003c\/p\u003e\n\u003cp\u003eThis peptide blend combines CJC-1295 (No DAC) and Ipamorelin, two complementary growth hormone secretagogues that act on distinct receptor pathways to amplify GH release.\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eMechanistic Claims\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\u003cstrong\u003eCJC-1295 (No DAC, 5 mg)\u003c\/strong\u003e\u003c\/li\u003e\n\u003cul\u003e\n\u003cli\u003eSynthetic GHRH analog retaining 29 amino acids of native GHRH with four substitutions for stability and receptor affinity.\u003c\/li\u003e\n\u003cli\u003eStimulates pituitary GHRH receptors to increase pulsatile GH secretion.\u003c\/li\u003e\n\u003cli\u003eElevates circulating IGF-1 levels, supporting anabolic and regenerative pathways.\u003c\/li\u003e\n\u003cli\u003eMimics natural GH release patterns without prolonged receptor binding.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cli\u003e\u003cstrong\u003eIpamorelin (5 mg)\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cul\u003e\n\u003cli style=\"list-style-type: none;\"\u003e\n\u003cul\u003e\n\u003cli\u003eSynthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂).\u003c\/li\u003e\n\u003cli\u003eSelective ghrelin receptor agonist that triggers GH release from the pituitary.\u003c\/li\u003e\n\u003cli\u003eHigh potency with minimal off-target hormonal effects (does not significantly affect cortisol, prolactin, or ACTH).\u003c\/li\u003e\n\u003cli\u003eProvides a clean GH stimulation profile compared to other GHS compounds.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSynergistic Potential\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eDual receptor targeting (GHRH + ghrelin) amplifies GH release.\u003c\/li\u003e\n\u003cli\u003ePromotes IGF-1 elevation while maintaining physiological GH pulsatility.\u003c\/li\u003e\n\u003cli\u003eOffers a balanced approach to studying growth hormone dynamics without excessive endocrine disruption.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eResearch Applications\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eGrowth hormone secretion and regulation studies\u003c\/li\u003e\n\u003cli\u003eIGF-1 mediated anabolic and regenerative pathways\u003c\/li\u003e\n\u003cli\u003eComparative analysis of GHRH vs. ghrelin receptor agonism\u003c\/li\u003e\n\u003cli\u003eEndocrine signaling and pituitary function models\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003c!--EndFragment --\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCJC 1295 Ipamorelin Research\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eCJC-1295 and ipamorelin have both been researched for their potential to stimulate growth hormone production.\u003c\/p\u003e\n\u003cdiv class=\"relative\"\u003e\n\u003cdiv class=\"mt-4 md:mt-6\"\u003e\n\u003cdiv dir=\"ltr\" class=\"mt-5\"\u003e\n\u003cdiv class=\"prose text-[0.9375rem] sm:text-base leading-[1.5] text-fg-base markdown\"\u003eIpamorelin is a potent and selective GH secretagogue with unique properties that differentiate it from other GH-releasing peptides. Its ability to selectively stimulate GH release without affecting other hormones, along with its potential applications in body composition, make it a promising candidate for further clinical development.\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cem\u003eGrowth Hormone Release\u003c\/em\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eIn GHRH knockout mice, CJC-1295 administration normalized body weight and length, demonstrating its potential in treating growth deficiencies. Daily administration was more effective than less frequent \u003cspan class=\"whitespace-nowrap\"\u003edosing.\u003csup\u003e1\u003c\/sup\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan class=\"whitespace-nowrap\"\u003eIn healthy subjects, CJC-1295 led to dose-dependent increases in GH and IGF-I levels, with effects lasting up to 28 days. In the study, CJC-1295 was well-tolerated with no serious adverse reactions reported, suggesting its potential utility as a therapeutic agent.\u003csup\u003e2\u003c\/sup\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan class=\"whitespace-nowrap\"\u003eIpamorelin mimics the action of ghrelin by binding to the ghrelin receptor (GHSR) in the brain, which leads to the selective stimulation of GH release from the pituitary gland. This mechanism is similar to that of GHRH, but ipamorelin does not significantly affect the release of other hormones such as ACTH or cortisol.\u003csup\u003e3\u003c\/sup\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan class=\"whitespace-nowrap\"\u003eIn animal studies, ipamorelin has been shown to increase longitudinal bone growth and body weight gain in a dose-dependent manner. It enhances GH release without affecting other growth factors like IGF-I, suggesting a direct effect on growth processes.\u003csup\u003e4\u003c\/sup\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cspan class=\"whitespace-nowrap\"\u003eIn vivo, ipamorelin shows dose-proportional pharmacokinetics with a short half-life and effectively stimulated GH release across various doses.\u003csup\u003e5\u003c\/sup\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cspan class=\"whitespace-nowrap\"\u003eReferences\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003col\u003e\n\u003cli\u003eAlba, M., Fintini, D., Sagazio, A., Lawrence, B., Castaigne, J., Frohman, L., \u0026amp; Salvatori, R. (2006). Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.. \u003cem\u003eAmerican journal of physiology. Endocrinology and metabolism\u003c\/em\u003e, 291 6, E1290-4 . \u003ca rel=\"noopener\" href=\"https:\/\/doi.org\/10.1152\/AJPENDO.00201.2006\" target=\"_blank\"\u003ehttps:\/\/doi.org\/10.1152\/AJPENDO.00201.2006\u003c\/a\u003e.\u003c\/li\u003e\n\u003cli\u003eTeichman, S., Neale, A., Lawrence, B., Gagnon, C., Castaigne, J., \u0026amp; Frohman, L. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.. \u003cem\u003eThe Journal of clinical endocrinology and metabolism\u003c\/em\u003e, 91 3, 799-805 . \u003ca rel=\"noopener\" href=\"https:\/\/doi.org\/10.1210\/JC.2005-1536\" target=\"_blank\"\u003ehttps:\/\/doi.org\/10.1210\/JC.2005-1536\u003c\/a\u003e.\u003c\/li\u003e\n\u003cli\u003eRaun, K., Hansen, B., Johansen, N., Thøgersen, H., Madsen, K., Ankersen, M., \u0026amp; Andersen, P. (1998). Ipamorelin, the first selective growth hormone secretagogue.. \u003cem\u003eEuropean journal of endocrinology\u003c\/em\u003e, 139 5, 552-61 . \u003ca rel=\"noopener\" href=\"https:\/\/doi.org\/10.1530\/EJE.0.1390552\" target=\"_blank\"\u003ehttps:\/\/doi.org\/10.1530\/EJE.0.1390552\u003c\/a\u003e.\u003c\/li\u003e\n\u003cli\u003eJohansen, P., Nowak, J., Skjaerbaek, C., Flyvbjerg, A., Andreassen, T., Wilken, M., \u0026amp; Orskov, H. (1999). Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats.. \u003cem\u003eGrowth hormone \u0026amp; IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society\u003c\/em\u003e, 9 2, 106-13 . \u003ca rel=\"noopener\" href=\"https:\/\/doi.org\/10.1054\/GHIR.1999.9998\" target=\"_blank\"\u003ehttps:\/\/doi.org\/10.1054\/GHIR.1999.9998\u003c\/a\u003e.\u003c\/li\u003e\n\u003cli\u003eGobburu, J., Agersø, H., Jusko, W., \u0026amp; Ynddal, L. (1999). Pharmacokinetic-Pharmacodynamic Modeling of Ipamorelin, a Growth Hormone Releasing Peptide, in Human Volunteers. \u003cem\u003ePharmaceutical Research\u003c\/em\u003e, 16, 1412-1416. \u003ca rel=\"noopener\" href=\"https:\/\/doi.org\/10.1023\/A:1018955126402\" target=\"_blank\"\u003ehttps:\/\/doi.org\/10.1023\/A:1018955126402\u003c\/a\u003e.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003e\u003cstrong\u003eLabel-- Peptide Information\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable style=\"width: 99.9363%; height: 298.344px;\"\u003e\n\u003cthead\u003e\n\u003ctr style=\"height: 10px;\"\u003e\n\u003cth style=\"width: 29.4596%; height: 10px;\"\u003e\n\u003cp\u003eProperty\u003c\/p\u003e\n\u003c\/th\u003e\n\u003cth style=\"width: 70.2205%; height: 10px;\"\u003e\n\u003cp\u003eValue\u003c\/p\u003e\n\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr style=\"height: 35.5938px;\"\u003e\n\u003ctd style=\"width: 29.4596%; height: 35.5938px;\"\u003e\n\u003cp\u003ePeptide Name\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd style=\"width: 70.2205%; height: 35.5938px;\"\u003e\n\u003cp\u003eCJC 1295\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"height: 74.7812px;\"\u003e\n\u003ctd style=\"width: 29.4596%; height: 74.7812px;\"\u003e\n\u003cp\u003ePeptide Sequence\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd style=\"width: 70.2205%; height: 74.7812px;\"\u003e\n\u003cp\u003eTyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala- Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"height: 35.5938px;\"\u003e\n\u003ctd style=\"width: 29.4596%; height: 35.5938px;\"\u003e\n\u003cp\u003eMolecular Formula\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd style=\"width: 70.2205%; height: 35.5938px;\"\u003e\n\u003cp\u003eC165H269N47O46\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"height: 35.5938px;\"\u003e\n\u003ctd style=\"width: 29.4596%; height: 35.5938px;\"\u003e\n\u003cp\u003eMolecular Weight\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd style=\"width: 70.2205%; height: 35.5938px;\"\u003e\n\u003cp\u003e\u003cspan\u003e3647.2\u003c\/span\u003e\u003cspan\u003e \u003c\/span\u003e\u003cspan\u003eg\/mol\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"height: 35.5938px;\"\u003e\n\u003ctd style=\"width: 29.4596%; height: 35.5938px;\"\u003e\n\u003cp\u003eCAS Number\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd style=\"width: 70.2205%; height: 35.5938px;\"\u003e\n\u003cp\u003e446262-90-4\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"height: 35.5938px;\"\u003e\n\u003ctd style=\"width: 29.4596%; height: 35.5938px;\"\u003e\n\u003cp\u003ePubChem CID\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd style=\"width: 70.2205%; height: 35.5938px;\"\u003e\n\u003cp\u003e\u003cspan\u003e91971820\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"height: 35.5938px;\"\u003e\n\u003ctd style=\"width: 29.4596%; height: 35.5938px;\"\u003e\n\u003cp\u003eSynonyms\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd style=\"width: 70.2205%; height: 35.5938px;\"\u003e\n\u003cp\u003eCJC 1295, CJC-1295, 62RC32V9N7, DTXSID501027567\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp style=\"text-align: left;\"\u003e \u003c\/p\u003e\n\u003ctable style=\"width: 99.9363%;\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth style=\"width: 28.8112%;\"\u003eProperty\u003c\/th\u003e\n\u003cth style=\"width: 70.6757%;\"\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 28.8112%;\"\u003ePeptide Name\u003c\/td\u003e\n\u003ctd style=\"width: 70.6757%;\"\u003eIpamorelin\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 28.8112%;\"\u003ePeptide Sequence\u003c\/td\u003e\n\u003ctd style=\"width: 70.6757%;\"\u003eAib-His-D-2Nal-D-Phe-Lys\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 28.8112%;\"\u003eMolecular Formula\u003c\/td\u003e\n\u003ctd style=\"width: 70.6757%;\"\u003eC38H49N9O5\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 28.8112%;\"\u003eMolecular Weight\u003c\/td\u003e\n\u003ctd style=\"width: 70.6757%;\"\u003e711.9 g\/mol\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 28.8112%;\"\u003eCAS Number\u003c\/td\u003e\n\u003ctd style=\"width: 70.6757%;\"\u003e170851-70-4\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 28.8112%;\"\u003ePubChem CID\u003c\/td\u003e\n\u003ctd style=\"width: 70.6757%;\"\u003e9831659\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 28.8112%;\"\u003eSynonyms\u003c\/td\u003e\n\u003ctd style=\"width: 70.6757%;\"\u003e170851-70-4, Ipamorelin [INN], NNC-26-0161, UNII-Y9M3S784Z6\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eDosage-- \u003cstrong\u003eThis PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY.\u003c\/strong\u003e\u003cspan\u003e This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food or cosmetic.\u003c\/span\u003e\u003c\/p\u003e","brand":"Biolongevity Labs","offers":[{"title":"Default Title","offer_id":47947430658203,"sku":"CJIP55","price":11953.0,"currency_code":"INR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0613\/3694\/4795\/files\/CJIP55-cjc-1295-and-ipamorelin-blend-10mg-no-dac-RET.jpg?v=1770933379","url":"https:\/\/fmihealth.com\/products\/cjc-1295-and-ipamorelin-blend-10mg-no-dac-biolongevity-labs","provider":"FMI health","version":"1.0","type":"link"}